A RANDOMIZED, PROSPECTIVE, DOUBLE-BLINDED TRIAL OF CYCLOSPORINE VS OG37-325 IN CADAVERIC RENAL-TRANSPLANTATION - A PRELIMINARY-REPORT

Authors
HENRY ML TESI RJ ELKHAMMAS EA FERGUSON RM",BOLLINGER,LEICHTMAN,SCHROEDER,STARZL
Citation
Ml. Henry et al., A RANDOMIZED, PROSPECTIVE, DOUBLE-BLINDED TRIAL OF CYCLOSPORINE VS OG37-325 IN CADAVERIC RENAL-TRANSPLANTATION - A PRELIMINARY-REPORT, Transplantation, 55(4), 1993, pp. 748-752
Citations number
20
Categorie Soggetti
Immunology,Surgery
Journal title
Transplantation → ACNP
ISSN journal
00411337
Volume
55
Issue
4
Year of publication
1993
Pages
748 - 752
Database
ISI
SICI code
0041-1337(1993)55:4<748:ARPDTO>2.0.ZU;2-G
Abstract
The efficacy of cyclosporine is documented, but it has side effects th at are troublesome. Another compound, OG37-325, has been identified th at appears to have similar efficacy, but less nephrotoxicity. This stu dy was designed to address the benefits and toxicities of cyclosporine and OG37-325 in a prospective, randomized, double-blinded trial in ca daveric renal transplant recipients. The preliminary results demonstra te similar outcomes in terms of patient and graft survival, but sugges t less nephrotoxicity in the OG37-325-treated patients. longer follow- up will delineate the utility of OG37-325 in solid-organ transplantati on.